Rational engineering of allosteric protein switches by in silico prediction of domain insertion sites.

Journal: Nature methods
Published Date:

Abstract

Domain insertion engineering is a powerful approach to juxtapose otherwise separate biological functions, resulting in proteins with new-to-nature activities. A prominent example are switchable protein variants, created by receptor domain insertion into effector proteins. Identifying suitable, allosteric sites for domain insertion, however, typically requires extensive screening and optimization. We present ProDomino, a machine learning pipeline to rationalize domain recombination, trained on a semisynthetic protein sequence dataset derived from naturally occurring intradomain insertion events. ProDomino robustly identifies domain insertion sites in proteins of biotechnological relevance, which we experimentally validated in Escherichia coli and human cells. Finally, we used light- and chemically regulated receptor domains as inserts and demonstrate the rapid, model-guided creation of potent, single-component opto- and chemogenetic protein switches. These include novel CRISPR-Cas9 and -Cas12a variants for inducible genome engineering in human cells. Our work enables one-shot domain insertion engineering and substantially accelerates the design of customized allosteric proteins.

Authors

  • Benedict Wolf
    Center for Digital Health, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Pegi Shehu
    Institute of Pharmacy and Molecular Biotechnology, Faculty of Engineering Sciences, Heidelberg University, Heidelberg, Germany.
  • Luca Brenker
    Institute of Pharmacy and Molecular Biotechnology, Faculty of Engineering Sciences, Heidelberg University, Heidelberg, Germany.
  • Anna-Lisa von Bachmann
    Institute of Pharmacy and Molecular Biotechnology, Faculty of Engineering Sciences, Heidelberg University, Heidelberg, Germany.
  • Ann-Sophie Kroell
    Institute of Pharmacy and Molecular Biotechnology, Faculty of Engineering Sciences, Heidelberg University, Heidelberg, Germany.
  • Nicholas Southern
    Institute of Pharmacy and Molecular Biotechnology, Faculty of Engineering Sciences, Heidelberg University, Heidelberg, Germany.
  • Stefan Holderbach
    Institute of Pharmacy and Molecular Biotechnology, Faculty of Engineering Sciences, Heidelberg University, Heidelberg, Germany.
  • Joshua Eigenmann
    Institute of Pharmacy and Molecular Biotechnology, Faculty of Engineering Sciences, Heidelberg University, Heidelberg, Germany.
  • Sabine Aschenbrenner
    Institute of Pharmacy and Molecular Biotechnology, Faculty of Engineering Sciences, Heidelberg University, Heidelberg, Germany.
  • Jan Mathony
    Institute of Pharmacy and Molecular Biotechnology, Faculty of Engineering Sciences, Heidelberg University, Heidelberg, Germany. jan.mathony@uni-heidelberg.de.
  • Dominik Niopek
    Institute of Pharmacy and Molecular Biotechnology, Faculty of Engineering Sciences, Heidelberg University, Heidelberg, Germany. dominik.niopek@uni-heidelberg.de.

Keywords

No keywords available for this article.